MX2008011216A - 1,5-dihidro-imidazol-2-onas 4-amino-1,5-substituidas. - Google Patents
1,5-dihidro-imidazol-2-onas 4-amino-1,5-substituidas.Info
- Publication number
- MX2008011216A MX2008011216A MX2008011216A MX2008011216A MX2008011216A MX 2008011216 A MX2008011216 A MX 2008011216A MX 2008011216 A MX2008011216 A MX 2008011216A MX 2008011216 A MX2008011216 A MX 2008011216A MX 2008011216 A MX2008011216 A MX 2008011216A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- lower alkyl
- substituted
- halogen
- heteroaryl
- Prior art date
Links
- QSTJOOUALACOSX-UHFFFAOYSA-N 1,5-dihydroimidazol-2-one Chemical class O=C1NCC=N1 QSTJOOUALACOSX-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 2
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a los compuestos de la fórmula general (I), en donde R1 es -(CH2)n-arilo o-(CH2)n- heteroarilo, en donde tales grupos están substituidos o no substituidos por uno o más substituyentes seleccionados del grupo que consiste de halógeno, alquilo inferior substituido por halógeno, alcoxi de C1-6, alquilo inferior, ciano, nitro, -O-alquilo inferior substituido por halógeno o morfolinilo; R2 es -(CH2)n-arilo o-(CH2)n-heteroarilo, en donde tales grupos están substituidos o no substituidos por uno o más substituyentes, seleccionados del grupo que consiste de alquilo inferior, alcoxi inferior, halógeno o -N(alquilo inferior)2; R3 es hidrógeno o alquilo inferior; R4 es -(CH2)n-arilo o -(CH2)n-heteroarilo, en donde tales grupos están substituidos o no substituidos por uno o más substituyentes seleccionados del grupo que consiste de halógeno o alcoxi inferior, o es alquilo inferior, -(CH2)n-cicloalquilo; o R3 y R4 forman junto con el átomo de N un anillo heterocíclico; n es 0, 1 ó 2; y a las sales de adición de los mismos farmacéuticamente aceptables. Se han encontrado que los compuestos de la fórmula general I o sus formas tautoméricas son buenos inhibidores del transportador 1 de la glicina (GlyT-1), y que los mismos tienen una buena selectividad con respecto a los inhibidores del transportador 2 de glicina GlyT-2), útiles para el tratamiento de la esquizofrenia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06110812 | 2006-03-08 | ||
| PCT/EP2007/051824 WO2007101802A1 (en) | 2006-03-08 | 2007-02-27 | 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008011216A true MX2008011216A (es) | 2008-09-11 |
Family
ID=38050076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008011216A MX2008011216A (es) | 2006-03-08 | 2007-02-27 | 1,5-dihidro-imidazol-2-onas 4-amino-1,5-substituidas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7553862B2 (es) |
| EP (1) | EP1994009A1 (es) |
| JP (1) | JP4913164B2 (es) |
| KR (1) | KR101027235B1 (es) |
| CN (1) | CN101395142B (es) |
| AU (1) | AU2007222446B2 (es) |
| BR (1) | BRPI0708607A2 (es) |
| CA (1) | CA2642859A1 (es) |
| IL (1) | IL193483A (es) |
| MX (1) | MX2008011216A (es) |
| WO (1) | WO2007101802A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2468546T3 (es) * | 2006-11-09 | 2014-06-16 | Probiodrug Ag | Nuevos inhibidores de glutaminil ciclasa |
| US8420684B2 (en) * | 2006-11-09 | 2013-04-16 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009513539A (ja) * | 2003-07-11 | 2009-04-02 | ベーリンガー・インゲルハイム・フエトメデイカ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | ベンゾジアゼピンレセプターのアルファ３サブユニットに対する選択性を有する化合物を用いて中枢神経系障害を治療または予防する方法 |
| BRPI0415833A (pt) | 2003-10-23 | 2007-01-02 | Hoffmann La Roche | derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos |
-
2007
- 2007-02-27 CN CN2007800073091A patent/CN101395142B/zh not_active Expired - Fee Related
- 2007-02-27 MX MX2008011216A patent/MX2008011216A/es active IP Right Grant
- 2007-02-27 WO PCT/EP2007/051824 patent/WO2007101802A1/en not_active Ceased
- 2007-02-27 AU AU2007222446A patent/AU2007222446B2/en not_active Ceased
- 2007-02-27 JP JP2008557718A patent/JP4913164B2/ja not_active Expired - Fee Related
- 2007-02-27 BR BRPI0708607-5A patent/BRPI0708607A2/pt not_active IP Right Cessation
- 2007-02-27 CA CA002642859A patent/CA2642859A1/en not_active Abandoned
- 2007-02-27 EP EP07726523A patent/EP1994009A1/en not_active Withdrawn
- 2007-02-27 KR KR1020087021921A patent/KR101027235B1/ko not_active Expired - Fee Related
- 2007-03-01 US US11/712,783 patent/US7553862B2/en not_active Expired - Fee Related
-
2008
- 2008-08-14 IL IL193483A patent/IL193483A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007222446A1 (en) | 2007-09-13 |
| KR101027235B1 (ko) | 2011-04-06 |
| JP4913164B2 (ja) | 2012-04-11 |
| WO2007101802A1 (en) | 2007-09-13 |
| US20070213384A1 (en) | 2007-09-13 |
| IL193483A (en) | 2012-08-30 |
| JP2009529020A (ja) | 2009-08-13 |
| CN101395142A (zh) | 2009-03-25 |
| US7553862B2 (en) | 2009-06-30 |
| CN101395142B (zh) | 2012-03-28 |
| BRPI0708607A2 (pt) | 2011-06-07 |
| AU2007222446B2 (en) | 2011-08-18 |
| EP1994009A1 (en) | 2008-11-26 |
| CA2642859A1 (en) | 2007-09-13 |
| KR20080091856A (ko) | 2008-10-14 |
| IL193483A0 (en) | 2009-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| EA200401431A1 (ru) | Производные триазола в качестве антагонистов рецептора тахикинина | |
| WO2006109075A3 (en) | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 | |
| TW200732329A (en) | Aryl-isoxazolo-4-yl-oxadiazole derivatives | |
| WO2008087611A3 (en) | Pyrrolidine- and piperidine- bis-amide derivatives | |
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| MX2012003499A (es) | Inhibidores de demetilasa-1 especificos de lisina y su uso. | |
| WO2010131922A4 (en) | Amide compound, preparation method thereof and pharmaceutical composition comprising same | |
| HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
| NO20073667L (no) | [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser | |
| WO2008108380A3 (en) | Pyrrole compounds | |
| MY136959A (en) | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof | |
| EA201101334A1 (ru) | Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их | |
| MX2016006685A (es) | Compuestos heterociclicos de n-acilimino. | |
| NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| NO20071112L (no) | Nye heterosykliske karboksylsyreamidderivater | |
| MX2010000658A (es) | Derivados de pirimidina 934. | |
| MX2009009121A (es) | Aminoamidas como antagonistas de orexina. | |
| PH12013501572A1 (en) | 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators | |
| PE20120732A1 (es) | Agonistas del receptor de esfingosina-1-fosfato | |
| DK167395B1 (da) | 2-phenyl-hexahydro-1,2,4-triazin-3,5-dioner, fremgangsmaade til deres fremstilling og dyrelaegemiddel deraf | |
| WO2007147770A3 (en) | Substituted phenyl methanone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |